Puma begins Phase II trial of cancer drug in solid tumour patients

US-based Puma Biotechnology has started Phase II clinical study of its lead drug candidate PB272 (neratinib) as a single agent for the treatment of patients with solid tumours and activating HER2 mutation (basket trial).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news